Pittsburgh, PA Clinical Trials Report — May 2026

For patients and healthy volunteers in Pittsburgh, PA, May 2026 brings a mix of urgent opportunities and fresh avenues to contribute to medical research. With 1,185 clinical trials currently recruiting across 392 research facilities in the city, there are numerous ways to get involved. This month, a significant number of trials are nearing their enrollment deadlines, making prompt action crucial for interested individuals.

Act Now: Trials Closing Soon in Pittsburgh

A total of 80 clinical trials are scheduled to conclude within the next 90 days in Pittsburgh. This urgency is particularly relevant for healthy volunteers, as 15 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a valuable chance to contribute to medical advancements before their enrollment windows close.

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various cancers, chronic pain, and cardiovascular conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Cancer (4 trials)
• Primary peritoneal cancer (3 trials)
• Chronic pain (3 trials)
• NSCLC (2 trials)
• Metastatic cancer (2 trials)
• Metastatic NUT carcinoma (2 trials)
• Chronic pancreatitis (2 trials)
• Breast cancer (2 trials)
• Cardiovascular diseases (2 trials)
• Asthma (2 trials)

New Research Opportunities Emerge This Month

This May, Pittsburgh saw the opening of 24 new clinical trials, a notable increase from the 11 trials that launched in April 2026. This surge in new studies underscores Pittsburgh's dynamic research environment. These new trials span various types of interventions:

• Drug trials (12)
• Behavioral studies (5)
• Other types of studies (5)
• Device trials (3)
• Procedure-based trials (3)
• Radiation studies (2)

New trials this month are exploring a range of conditions, including acute leukemia, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), adrenalectomy, alcohol use disorder, alveolar bone loss, atopic dermatitis, and studies involving caregivers and cerebral edema.

Notable New Trials in Pittsburgh

May brings several high-profile new trials to Pittsburgh, including significant Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges:

• AstraZeneca is initiating a notable Phase 3 study, NCT07611110, "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)." This trial aims for 670 participants to demonstrate the superiority of AZD2265 relative to standard of care treatments by assessing radiographic progression-free survival and overall survival in participants with metastatic castration-resistant prostate cancer.
• Tarsus Pharmaceuticals, Inc. is sponsoring NCT07562087, "A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure." This Phase 2 study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to 700 healthy adult participants.
• Apollo Therapeutics Ltd is behind NCT07599813, "A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis." This multicenter, randomized, double-blind, placebo-controlled study involves 280 participants.
• The University of Pittsburgh is sponsoring NCT07598539, "Knee Replacement Rehabilitation Care Pathways." This study, involving 275 participants, will develop and test new care pathways to address disparities in rehabilitation and recovery after knee replacement surgery based on factors like race, sex, income, and geographic location.
• NeurOptics Inc. is leading NCT07573150, "Pupillometry in Identifying Risk of Postoperative Opioid-induced Respiratory Depression in Children Undergoing Tonsillectomy." This study involves 300 children and will evaluate whether quantitative pupillometry measurements can identify those at risk for postoperative opioid-induced respiratory depression, a serious complication.
• Rochester General Hospital is sponsoring NCT07576036, "International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia." This study aims to identify 800 patients from electronic medical records to understand the relationship between ODS and rapid correction of hyponatremia.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 24 new trials launched this month, 7 are actively seeking healthy volunteers. Across Pittsburgh, a total of 123 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Pittsburgh's Leading Research Facilities

Pittsburgh is home to some of Pennsylvania's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Pittsburgh (137 trials)
• University of Pittsburgh Medical Center (136 trials)
• University of Pittsburgh Cancer Institute (UPCI) (88 trials)
• UPMC Hillman Cancer Center (83 trials)
• Allegheny General Hospital (65 trials)
• Children's Hospital of Pittsburgh of UPMC (57 trials)
• UPMC Children's Hospital of Pittsburgh (46 trials)
• UPMC-Passavant Hospital (40 trials)
• Research Site (38 trials)
• Allegheny Health Network (33 trials)
• UPMC-Saint Clair Hospital Cancer Center (31 trials)
• UPMC-Saint Margaret (28 trials)

These institutions offer a broad spectrum of research, from oncology at the University of Pittsburgh Cancer Institute and UPMC Hillman Cancer Center, to pediatric care at Children's Hospital of Pittsburgh of UPMC, and diverse medical fields across the University of Pittsburgh and UPMC network.

Broadening Your Search: Nearby Options in Pennsylvania

While Pittsburgh offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Pennsylvania. Cities with active trials include Philadelphia (24 trials), DuBois (3 trials), Erie (3 trials), Danville (2 trials), Camp Hill (2 trials), Hatboro (2 trials), Hershey (1 trial), and Lancaster (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 24 new trials launched this month, 20 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children, 3 are female-only, and 1 is male-only. Academic institutions continue to play a vital role in Pittsburgh's research ecosystem, with the University of Pittsburgh sponsoring 5 new studies this month. Industry sponsors like Altesa Biosciences, Inc., Apollo Therapeutics Ltd, and AstraZeneca are also driving significant research efforts.

As Pittsburgh continues to be a hub for medical innovation, the coming months are expected to bring even more diverse opportunities for individuals to contribute to the future of healthcare and advance scientific understanding.